These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 7673726)

  • 1. Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory.
    Giovarelli M; Musiani P; Modesti A; Dellabona P; Casorati G; Allione A; Consalvo M; Cavallo F; di Pierro F; De Giovanni C
    J Immunol; 1995 Sep; 155(6):3112-23. PubMed ID: 7673726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An efficient Th2-type memory follows CD8+ lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4.
    Pericle F; Giovarelli M; Colombo MP; Ferrari G; Musiani P; Modesti A; Cavallo F; Di Pierro F; Novelli F; Forni G
    J Immunol; 1994 Dec; 153(12):5659-73. PubMed ID: 7989764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, IFN-alpha, IFN-gamma, and TNF-alpha.
    Musiani P; Allione A; Modica A; Lollini PL; Giovarelli M; Cavallo F; Belardelli F; Forni G; Modesti A
    Lab Invest; 1996 Jan; 74(1):146-57. PubMed ID: 8569177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene.
    Cavallo F; Giovarelli M; Gulino A; Vacca A; Stoppacciaro A; Modesti A; Forni G
    J Immunol; 1992 Dec; 149(11):3627-35. PubMed ID: 1358974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Local release of interleukin-10 by transfected mouse adenocarcinoma cells exhibits pro- and anti-inflammatory activity and results in a delayed tumor rejection.
    Di Carlo E; Coletti A; Modesti A; Giovarelli M; Forni G; Musiani P
    Eur Cytokine Netw; 1998 Mar; 9(1):61-8. PubMed ID: 9613679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A "stealth effect": adenocarcinoma cells engineered to express TRAIL elude tumor-specific and allogeneic T cell reactions.
    Giovarelli M; Musiani P; Garotta G; Ebner R; Di Carlo E; Kim Y; Cappello P; Rigamonti L; Bernabei P; Novelli F; Modesti A; Coletti A; Ferrie AK; Lollini PL; Ruben S; Salcedo T; Forni G
    J Immunol; 1999 Nov; 163(9):4886-93. PubMed ID: 10528190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of cancer gene therapy in aging: adenocarcinoma cells engineered to release IL-2 are rejected but do not induce tumor specific immune memory in old mice.
    Provinciali M; Argentati K; Tibaldi A
    Gene Ther; 2000 Apr; 7(7):624-32. PubMed ID: 10819579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response.
    Cavallo F; Martin-Fontecha A; Bellone M; Heltai S; Gatti E; Tornaghi P; Freschi M; Forni G; Dellabona P; Casorati G
    Eur J Immunol; 1995 May; 25(5):1154-62. PubMed ID: 7539748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-Fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory.
    Consalvo M; Mullen CA; Modesti A; Musiani P; Allione A; Cavallo F; Giovarelli M; Forni G
    J Immunol; 1995 May; 154(10):5302-12. PubMed ID: 7730633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mice vaccination with interleukin 12-transduced colon cancer cells potentiates rejection of syngeneic non-organ-related tumor cells.
    Adris S; Chuluyan E; Bravo A; Berenstein M; Klein S; Jasnis M; Carbone C; Chernajovsky Y; Podhajcer OL
    Cancer Res; 2000 Dec; 60(23):6696-703. PubMed ID: 11118055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nature and potential of the reactive response to mouse mammary adenocarcinoma cells engineered with interleukin-2, interleukin-4 or interferon-gamma genes.
    Musiani P; Modesti A; Brunetti M; Modica A; Vitullo P; Gulino A; Bosco MC; Colombo MP; Nanni P; Cavallo F
    Nat Immun; 1994; 13(2-3):93-101. PubMed ID: 8173240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor effect of interleukin (IL)-12 in the absence of endogenous IFN-gamma: a role for intrinsic tumor immunogenicity and IL-15.
    Gri G; Chiodoni C; Gallo E; Stoppacciaro A; Liew FY; Colombo MP
    Cancer Res; 2002 Aug; 62(15):4390-7. PubMed ID: 12154045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants.
    Allione A; Consalvo M; Nanni P; Lollini PL; Cavallo F; Giovarelli M; Forni M; Gulino A; Colombo MP; Dellabona P
    Cancer Res; 1994 Dec; 54(23):6022-6. PubMed ID: 7954438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different tumours, transduced with different cytokine genes as G-CSF and IL-2, show inhibition of tumour take through neutrophil activation but differ in T cell functions.
    Stoppacciaro A; Forni G; Colombo MP
    Folia Biol (Praha); 1994; 40(1-2):89-99. PubMed ID: 7525363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune responsiveness to a murine mammary carcinoma modified to express B7-1, interleukin-12, or GM-CSF.
    Aruga E; Aruga A; Arca MJ; Lee WM; Yang NS; Smith JW; Chang AE
    Cancer Gene Ther; 1997; 4(3):157-66. PubMed ID: 9171934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IFN-alpha 1 gene expression into a metastatic murine adenocarcinoma (TS/A) results in CD8+ T cell-mediated tumor rejection and development of antitumor immunity. Comparative studies with IFN-gamma-producing TS/A cells.
    Ferrantini M; Giovarelli M; Modesti A; Musiani P; Modica A; Venditti M; Peretti E; Lollini PL; Nanni P; Forni G
    J Immunol; 1994 Nov; 153(10):4604-15. PubMed ID: 7963533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Th2-type CD4+ cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model.
    Fernando GJ; Stewart TJ; Tindle RW; Frazer IH
    J Immunol; 1998 Sep; 161(5):2421-7. PubMed ID: 9725239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor rejection and immune memory elicited by locally released LEC chemokine are associated with an impressive recruitment of APCs, lymphocytes, and granulocytes.
    Giovarelli M; Cappello P; Forni G; Salcedo T; Moore PA; LeFleur DW; Nardelli B; Di Carlo E; Lollini PL; Ruben S; Ullrich S; Garotta G; Musiani P
    J Immunol; 2000 Mar; 164(6):3200-6. PubMed ID: 10706711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B7-1 (CD80)-gene transfer combined with interleukin-12 administration elicits protective and therapeutic immunity against mouse hepatocellular carcinoma.
    Tatsumi T; Takehara T; Kanto T; Kuzushita N; Ito A; Kasahara A; Sasaki Y; Hori M; Hayashi N
    Hepatology; 1999 Aug; 30(2):422-9. PubMed ID: 10421650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism.
    Rakhmilevich AL; Janssen K; Hao Z; Sondel PM; Yang NS
    Cancer Gene Ther; 2000 Jun; 7(6):826-38. PubMed ID: 10880012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.